To compare the efficacy, safety, and cost of prophylactic low-dose ganciclovir with that of immunoglobulin in renal transplant recipients at risk for primary cytomegalovirus (CMV) disease.
Design and Setting:
A prospective, randomized trial at a 650-bed tertiary medical center hospital.
Fifty-one consecutive CMV-seronegative patients who received renal allografts from seropositive donors between March 1990 and April 1992.
Main Outcome Measures:
Patient and allograft survival, and the incidence and severity of CMV disease.
Cytomegalovirus prophylaxis with seven doses of intravenous immunoglobulin for 6-week periods (group 1, n=27) or low-dose intravenous ganciclovir for 3 weeks (group 2, n=24). Results were compared with those obtained in 23 CMV-seronegative historical positive donors between 1987 and 1989, and who did n-positive donors between 1987 and 1989, and who did not receive prophylaxis for CMV (group 3).
Both prophylactic regimens significantly reduced the incidence of invasive CMV infection (P<.05) and were well tolerated. However, the cost of ganciclovir ($350 per patient) was substantially less than that of immunoglobulin ($4000 per patient).
These data suggest that prophylactic ganciclovir therapy provides a cost-effective approach toward significantly improving the outcome of renal transplantation in recipients at risk for primary CMV disease.(Arch Surg. 1994;129:443-447)
David J. Conti, Brian M. Freed, Scott A. Gruber, Neil Lempert. Prophylaxis of Primary Cytomegalovirus Disease in Renal Transplant RecipientsA Trial of Ganciclovir vs Immunoglobulin. Arch Surg. 1994;129(4):443–447. doi:10.1001/archsurg.1994.01420280121016